LIFEVANTAGE CORP Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
LIFEVANTAGE CORP (LFVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum of 113.00% for the 9-month period ending 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum · last filed 2013-05-09
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2012 was 119.00%, a 4.80% decline from fiscal 2011.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2011 was 125.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 12 month |
|---|---|---|---|
| 2013-03-31 | 113.00% 10-Q · filed 2013-05-09 | ||
| 2012-12-31 | 113.00% 10-Q · filed 2013-02-07 | ||
| 2012-06-30 | 119.00% 10-K · filed 2012-09-10 | ||
| 2012-03-31 | 129.00% 10-Q · filed 2013-05-09 | ||
| 2011-12-31 | 129.00% 10-Q · filed 2013-02-07 | ||
| 2011-06-30 | 125.00% 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |